The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali – Novartis) has been approved by the FDA for use in combination with an aromatase inhibitor for first-line endocrine-based therapy in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Ribociclib is also available copackaged with the aromatase inhibitor letrozole (Femara, and generics) as Kisqali Femara Co-Pack. Ribociclib is the second CDK 4/6 inhibitor to be approved in the US for this indication; palbociclib (Ibrance) was the first.1 Abemaciclib (Verzenio), a third CDK 4/6 inhibitor, was recently approved and will be reviewed in a future issue.

STANDARD TREATMENT — An aromatase inhibitor, with or without the CDK 4/6 inhibitor palbociclib, is ... more      

Would you like to read the rest of this article?  Gain access below.